Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
7 clinical trials · Condition
◉ Watch Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
| Record | Firm | Date |
|---|---|---|
| DALY II USA/ MB-CART2019.1 for DLBCL (NCT04792489) | Miltenyi Biomedicine GmbH | 2021-05-25 |
| Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT02570542) | Memorial Sloan Kettering Cancer Center | 2015-10-01 |
| Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (NCT02348216) | Kite, A Gilead Company | 2015-04-21 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma (NCT01742988) | Curis, Inc. | 2012-12-01 |
Track Refractory Diffuse Large B-Cell Lymphoma (DLBCL) automatically
Every clearance here is in the API, with alerts when new ones post.